Not exact matches
«Your own data show that you received hundreds of complaints that your
EpiPen products failed to operate during life - threatening emergencies, including some situations in which
patients subsequently died,» the FDA wrote.
«You failed to thoroughly investigate multiple serious component and product failures for your
EpiPen products, including failures associated with
patient deaths and severe illness,» the warning read.
The PR fiasco forced the company to buttress its own
patient assistance and rebate programs for the
EpiPen and to introduce an authorized generic version of the device at half the price.
The generic drug company tripled the discount
patients can receive on the cost of
EpiPen to $ 300, up from the maximum $ 100 Mylan had previously offered with the use of its special «savings card.»
That means
patients who were paying
EpiPen's full $ 608 list price (for a package of two) can now get the epinephrine injection device, which is used to treat a potentially fatal allergic reaction known as anaphylaxis, for about half as much.
That could have a domino effect on the other middlemen between Mylan and the
patient, such as drug distributors, pharmacy benefit managers, and pharmacies, who might also have to settle for less revenue per
EpiPen sale.
Mylan's (myl)
EpiPen's price has ballooned about 400 % since 2008, rising from about a $ 100 list price to $ 500 today (many
patients are offered a $ 100 coupon for the injecting device, but it's often not enough to cover costs for American families, especially those who have health insurance with high deductibles).
Clinton went on to reiterate her position that drug price hikes should be linked with better
patient outcomes and demonstrated improvements in value, and demanded that Mylan «immediately reduce the price of
EpiPens.»
In a statement Monday, Mylan says it has tried to make
EpiPen accessible and affordable to people who really need it, offering rebate cards that allowed 80 % of
patients with commercial insurance to get the product for free last year.
While the drug maker has responded to the massive backlash over its extravagant price increase on the device by boosting its
patient assistance programs and introducing an authorized generic
EpiPen version at half the cost, CVS» topline price will still be significantly cheaper.
And on Thursday, Mylan expanded its discount program, offering up to $ 300 off the cost of
EpiPen with the use of a special «savings card,» thereby reducing the price for
patients paying out - of - pocket by half, the company said.
Mylan has defended its
EpiPen pricing by pointing to
patient assistance programs and coupons that reduce the device's cost.
She said that employers» increased use of high - deductible plans, one of the side - effects of the law, has resulted in
patients paying more out of pocket for the drug, and that's «where you're seeing a lot of noise around
EpiPen.»
A lot of that growth came from increasing
EpiPen prescriptions as the product became more mainstream: In the first seven years Mylan owned
EpiPen, the number of
patients using it grew 67 %, according to Bloomberg.
This company reduced the out - of - pocket costs of
EpiPen for some
patients last week amid a wave of criticism from lawmakers and the public over the rapid escalation in the product's price in the past few years.
Mylan: Deeply committed to ensuring
EpiPen access with
patient assistance programs.
Noting that Mylan had sought legislation to increase the number of
patients who receive prescriptions for
EpiPens, Rep. Mick Mulvaney, R-S.C.
March 30, 2017 UChicago Medicine research finds
patients face rising costs for
EpiPen allergy drug Commercially insured
patients who use the life - saving epinephrine auto - injector known as «
EpiPen» have experienced skyrocketing out - of - pocket costs since 2007, according to research published March 27 in JAMA Internal Medicine.
There is much outrage over the increase in
EpiPen pricing from the internet as well as from the
patients that need the life - saving medication.
While it's necessary to understand the bigger picture issues behind scandals, like
EpiPen and the outbreak in opioid usage, it's also crucial to remember
patients whose lives have changed thanks to hardworking medical sales reps.